Compare

Kuros Biosciences AG/Fr. KURN

1D1W1MYTD1Y5YMAX

About Kuros Biosciences AG

Kuros Biosciences AG is a biotechnology company focused on the development and commercialization of novel products for tissue repair and regeneration. The company's portfolio includes biomaterials and biologics aimed at enhancing bone healing in spinal, trauma, and cranio-maxillofacial surgeries. Headquartered in Schlieren, Switzerland, Kuros leverages its proprietary technologies to address unmet clinical needs in bone regeneration. The company's strategic positioning is strengthened by its focus on advanced biomaterial-based solutions, which differentiate its offering in the competitive regenerative medicine market.
Ticker
Fr. KURN
Sector
Health
Primary listing
XSWX
Employees
213
Headquarters
Schlieren, Switzerland
Website
kurosbio.com

KURN Metrics

BasicAdvanced
CHF 739M
102.59
CHF 0.18
0.74
-

Bulls say / Bears say

MagnetOs is gaining share quickly. H1 2026 medical-device sales rose 45% to USD 92.4 million, and the product became the third-largest bone-graft brand by US revenue, with more than 150,000 patients treated worldwide. (Kuros Biosciences)
Kuros has moved from growth without profits to a clearer earnings story. H1 adjusted EBITDA rose 61% to USD 12.5 million and the company delivered USD 4.4 million of net profit, while maintaining its 2026 growth and 2028 margin guidance. (Kuros Biosciences)
The addressable market could broaden materially as Kuros extends MagnetOs from spine into foot and ankle and trauma. Its three Level I studies and continuing Medtronic relationship provide potential clinical support and distribution reach for that expansion. (EarningsCalls.dev, Kuros Biosciences)
Cash and cash equivalents fell to USD 9.7 million at the end of June from USD 19.8 million at 2025 year-end. The decline reflects manufacturing investment and working-capital needs, leaving execution dependent on cash generation and an undrawn bridge facility. (Kuros Biosciences)
The US and Netherlands capacity build, alongside business-transformation spending, is still absorbing capital and temporarily weighing on margins. That creates a risk that rapid sales growth will not translate into equally rapid underlying cash-flow and profit growth. (Simply Wall St, Kuros Biosciences)
The expansion beyond spine still depends on clinical and commercial execution: ASTRA was only 14% enrolled, while PRECISE was 49% enrolled at the August update. Until these studies mature and new markets gain adoption, the longer-term growth case remains partly unproven. (EarningsCalls.dev)
Data summarised monthly by Lightyear AI. Last updated on 20 Sept 2026.

KURN Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

KURN Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing KURN

AllEURUSDGBP
Funds
Fund name
Fund size
Fr. KURN weighting
iShares Ageing Population€AGED
€822M0.06%
iShares MSCI World Small Cap$WSML
$9B0.01%
iShares MSCI World Small Cap€IUSN
€7.8B0.01%
iShares MSCI World Small Cap£WLDS
£6.7B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.